NCT00290953已完成2 期
A Double Blind, Randomized, Phase II-III Maintenance Study of SR48692 Versus Placebo in Patients With Extensive Stage Small Cell Lung Cancer Following a First Line Chemotherapy With Cisplatin + Etoposide
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 432
- 试验地点
- 14
- 主要终点
- - Overall survival (OS)
研究概览
简要总结
To demonstrate an increase in overall survival for patients with newly diagnosed extended stage small cell lung cancer when treated with SR48692 versus placebo, after an initial response (complete or partial response or stable) to first line cisplatin plus etoposide.
Primary objective: comparison of overall survival between patients in the control arm and the meclinertant arm.
Secondary objectives: comparison of the progression free survival, the time to progression, the clinical benefit, the quality of life, the toxicity and safety between patients in the control arm and the meclinertant arm.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathological diagnosis: Histologically or cytologically proven SCLC.
- •Disease stage: extensive stage
- •Measurable disease by the RECIST criteria is required. Lesions that are present in previously irradiated area are non-measurable unless they have appeared or progressed since completion of the radiation.
- •Radiotherapy, if applicable, must have been completed at least 4 weeks before treatment under this protocol and the subject must have recovered from any acute toxicities of radiation.
- •Recovered from any surgical procedure(s).
- •Calculated creatinine clearance > 55 ml/min using the Cockcroft-Gault formula: Cr Cl in ml/min = (140-age) X (weight in kg) X (1.0 for men or 0.85 for women) / (72 X serum Cr in mg/dl).
- •Total bilirubin < two times the upper limit of the normal range at the institution and SGOT/AST < two times the upper limit of normal unless liver metastases are present.
- •ANC > 1.5 x 109/L and platelet count > 100 x 109/L.
- •Age >18 years.
- •Karnofsky Performance Status > 70% .
- •Subjects with no prior malignancy, or subjects with cured malignancies other than SCLC if: a) they are alive without disease recurrence for at least 5 years from the date of pathological diagnosis, and b) clinical expectation of disease recurrence is < 5% as documented in the medical record by the responsible physician, and c) they have not received any platinum-based therapy. Subjects with basal cell carcinoma or carcinoma in situ of the cervix may be eligible if adequately treated and clinical expectation of disease recurrence is < 5% as documented in the medical record by the responsible physician.
- •Infertile subjects or fertile subjects who use a medically acceptable contraceptive throughout the treatment period and for 3 months following cessation of treatment. Women of childbearing potential must have documentation of a negative, serum HCG pregnancy test. Subjects must be made aware, before entering this trial, of the risk in becoming pregnant or in fathering children.
- •Signed written informed consent (approved by the Ethics Committee) obtained prior to study entry.
排除标准
- •Limited disease.
- •Symptomatic brain metastases: a patient with brain and/or leptomeningeal metastases on computer tomography (CT) or Magnetic Resonance Imaging (MRI) scan may be included only if he/she is asymptomatic on neurologic exam and is not receiving corticosteroid therapy to control symptoms.
- •Concurrent active cancer, including cancer stable on adjuvant therapy.
- •Prior immunotherapy, biological therapy or chemotherapy for SCLC.
- •Radiotherapy: Prior radiation to non-symptomatic or non-life-threatening sites.Prior radiation therapy to all potential indicator lesions. Prior radiation therapy to some but not all indicator lesions is allowed.
- •Class III or IV congestive heart failure according to the New York Heart Association Classification.
- •History of allergic reactions to appropriate diuretics or antiemetics (e.g., 5-HT3 antagonists) to be administered in conjunction with protocol-directed chemotherapy.
- •Uncontrolled intercurrent illness.
- •Lactating or pregnant women.
- •Received any investigational drug within 30 days before beginning treatment with study drug.
结局指标
主要结局
- Overall survival (OS)
次要结局
- - Toxicity and safety assessment using NCI CTC version 2.0
- - Progression Free Survival (PFS)
- - Time to Progression (TTP)
- - Clinical Benefit assessed by Performance Status and body weight
- - Quality of Life using the LCSS and EuroQoL validated instruments
研究者
研究点 (14)
Loading locations...
相似试验
已完成
3 期
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate CancerProstatic NeoplasmsNCT00744497Bristol-Myers Squibb1,930
已完成
2 期
Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus GemcitabineNon Small Cell Lung CancerNCT00753714Genzyme, a Sanofi Company124
撤回
3 期
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT01266811Centocor, Inc.
已完成
3 期
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck CancersCarcinoma, Squamous Cell of the Head and NeckNCT01166542Oncolytics Biotech167
已完成
2 期
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLCNon Small Cell Lung CancerNCT00743938Bristol-Myers Squibb141